Magnum Audit Flags Governance Issues at Ben & Jerry’s Foundation Ahead of Spin-Off 
BOJ Faces Pressure for Clarity, but Neutral Rate Estimates Likely to Stay Vague 
IKEA Expands U.S. Manufacturing Amid Rising Tariffs and Supply Chain Strategy Shift 
Hikvision Challenges FCC Rule Tightening Restrictions on Chinese Telecom Equipment 
Spain’s Industrial Output Records Steady Growth in October Amid Revised September Figures 
Europe Confronts Rising Competitive Pressure as China Accelerates Export-Led Growth 
China’s Services Sector Posts Slowest Growth in Five Months as Demand Softens 
Trump Administration to Secure Equity Stake in Pat Gelsinger’s XLight Startup 
UPS MD-11 Crash Prompts Families to Prepare Wrongful Death Lawsuit 
Gold Prices Edge Higher as Markets Await Key U.S. PCE Inflation Data 
Asian Currencies Steady as Rupee Hits Record Low Amid Fed Rate Cut Bets 
ExxonMobil to Shut Older Singapore Steam Cracker Amid Global Petrochemical Downturn 
Asian Currencies Steady as Markets Await Fed Rate Decision; Indian Rupee Hits New Record Low 
Firelight Launches as First XRP Staking Platform on Flare, Introduces DeFi Cover Feature 
YouTube Agrees to Follow Australia’s New Under-16 Social Media Ban 
Microchip Technology Boosts Q3 Outlook on Strong Bookings Momentum 
Merck & Co Inc. gets the green light from the Japanese health ministry for its COVID-19 anti-viral pill. The health officials recommended the approval of the said medicine late last week.
The approval of the Merck coronavirus pill is said to be part of the country’s Prime Minister Fumio Kishida’s plan to introduce and distribute new treatments by the end of the year as the growing cases of Omicron variant infection is becoming a very serious concern.
According to Inquirer.net, the committee’s decision has led to the shipments of around 200,000 doses starting this weekend. This is just the preparation and start of the deliveries as per the announcement of the country’s prime minister.
“I am convinced the distribution of this drug is a major step forward for our nation’s COVID–19 handling,” Shigeyuki Goto, Japan’s health minister, told the press after the announcement of the panel’s approval of Merck’s COVID-19 treatment pill.
He added that some of the country’s pharmacies and medical institutions are expected to begin receiving the medicine as early as next Monday. Moreover, it was said that Japan is really laying bets on oral treatments to prevent cases of severe infections and deaths should a sixth wave of the pandemic arise.
Based on the report, Japan agreed to pay $1.2 billion to Merck and its partner Ridgeback Biotherapeutics for the shipment of 1.6 million courses of molnupiravir. PM Kishida also said last week, the government signed a deal for two million doses of another anti-viral treatment pill and this was developed by Pfizer.
In the U.S., health regulators also authorized the use of the Merck pill for some high-risk adult patients. Many countries are now rushing to purchase the said Merck’s molnupiravir due to promising results during trials.
“As a single oral medicine that can be taken at home, early treatment with molnupiravir significantly reduced the risk of hospitalization or death in patients at high risk for progressing to severe COVID-19,” Merck research laboratories president, Dr. Dean Y. Li, said in a press release. “Importantly for patients, there were markedly fewer deaths among those taking molnupiravir in our clinical study and we believe that it will be a critical addition to the measures available to help curb the impact of COVID-19 on patients, healthcare systems, and public health in Japan.”
